Century Therapeutics Conference Call Summary Company Overview - **Company**: Century Therapeutics (NasdaqGS: IPSC) - **Focus**: Development of iPSC-derived cell therapies with a strong emphasis on immune evasion technology [2][3] Key Programs CNTY-813 (Type 1 Diabetes Program) - **Description**: iPSC-derived beta islet cell replacement therapy with advanced immune evasion technology (AlloVation 5.0) - **Current Status**: In IND-enabling studies, expected IND submission by late 2026 - **Potential Impact**: Aims to provide a functional cure for Type 1 diabetes, addressing a significant unmet medical need for approximately 10 million patients globally [3][25] CNTY-308 (Alpha Beta T Cell Program) - **Description**: iPSC-derived T cell therapy targeting CD19 for B-cell-mediated autoimmune diseases - **Current Status**: Targeting clinical push within the year, leveraging the same AlloVation 5.0 technology - **Differentiation**: Claims to offer comparable efficacy to autologous T cells without the need for lymphodepletion [4][46] Technology and Innovation - **iPSC Advantages**: Unlimited scalability and ability to differentiate into any adult cell type, making them ideal for cell-based therapies [11][12] - **AlloVation 5.0**: Advanced immune evasion technology that includes: - Removal of Class I and Class II HLAs to prevent T cell response - Insertion of a universal pan-NK inhibitory ligand (CD300a TASR) to mitigate NK cell response - IgG-degrading protease to protect against antibody-mediated rejection [15][17][21] Clinical Development and Regulatory Path - **IND Submission Timeline**: On track for submission in late 2026, with positive feedback from the FDA regarding the evidence package [32][37] - **Clinical Trial Goals**: Focus on safety, engraftment, and functionality of cells, with a target to reduce or eliminate chronic immunosuppression [34][39] Market Opportunity - **Target Population**: Initial focus on severe Type 1 diabetes patients with multiple hypoglycemic events, estimated at 60,000 in the U.S. alone, with potential expansion to 200,000-250,000 patients [43][45] - **Long-term Vision**: Aiming for commercialization in the early 2030s, contingent on successful clinical data and regulatory approvals [38] Financial Position - **Cash Runway**: Recent capital raise extends cash runway to Q1 2029, covering key clinical milestones [54] Additional Insights - **Preclinical Data**: Extensive data supporting the efficacy of CNTY-813 and CNTY-308, including successful animal model results demonstrating normoglycemia and persistence of T cells [19][50] - **Competitive Landscape**: Acknowledgment of the competitive nature of the cell therapy space, with a commitment to high benchmarks for clinical outcomes [52] This summary encapsulates the critical elements discussed during the conference call, highlighting Century Therapeutics' strategic focus, innovative technologies, and market potential in the field of cell therapies.